Phones Still a Vital Part of Clinical Research
Applied Clinical Trials
In clinical trials, the need for globally accessible toll-free and other phone numbers for trial functions is vital.
In clinical trials, the need for globally accessible toll-free and other phone numbers for trial functions is vital. But because of the way international telephone carrier services are set up, phone numbers may be left inoperable.
According to Stephen Levenson, Vice President of Global Telecom Testing, international telecommunications companies rent phone lines from local carriers. These companies have no control over the line or service and are dependent on the local carrier. This may not sound problematic, until a number doesn't work. Then it could mean days of downtime to resolve issues.
Levenson's company offers multi-faceted in-country, live human testing of phone numbers. These tests are done within the country to attempt completing outbound calls to ensure the number(s) works. This is different than testing a number by computer, because computers can't determine if customers will be able to call the designated number from in-country local access points, if they can hear clearly, or if other call quality issues are present. Global Telecom Testing offers an additional service through its relationship with locally-based phone carriers to resolve phone issues directly.
Other issues with international calling and their local exchange carrier partners assume that an international telephone number is operational just because it has worked in the past. In addition, some countries or regions have no industry standard or phone company regulation.
Global Telecom Testing's technicians have discovered improper carrier provisioning, improper passcode designation, improper message authentication, echo, static, post dial delay, network inaccessibility, carrier activation failures, and on-site blocking of 800 numbers.
Levenson told Applied Clinical Trials, "What we have found over the past three years is up to 40% of these numbers are not operational when they are handed off to go live. This is a colossal fail for a clinical trial."
—Lisa Henderson
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
